IP Library Granted Patent US 7,550,295
Granted Patent B2
US 7,550,295 · App. 11/368,299 · Granted Jun 23, 2009

Method for molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase

Assignee: Sloan-Kettering Institute for Cancer Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,550,295
App. No.
11/368,299
Granted
Jun 23, 2009
Kind
B2
Abstract

This invention provides a modified vaccinia topoisomerase enzyme containing an affinity tag which is capable of facilitating purification of protein-DNA complexes away from unbound DNA. This invention further provides a modified sequence specific topoisomerase enzyme. This invention provides a method of ligating duplex DNAs, a method of molecular cloning of DNA, a method of synthesizing polynucleotides, and a method of gene targeting. Lastly, this invention provides a recombinant DNA molecule composed of segments of DNA which have been joined ex vivo by the use of a sequence specific topoisomerase and which has the capacity to transform a suitable host cell comprising a DNA sequence encoding polypeptide activity.

Claims (7)

1. A method for cloning DNA which comprises introducing into a cell ligated duplex DNA, wherein the ligated duplex DNA is obtained by contacting an acceptor duplex DNA which contains a 5′-OH terminus with a donor duplex DNA bound to a sequence specific type I topoisomerase, such that the donor duplex DNA is transferred to the ends of the acceptor DNA to which it can base pair.

2. The method of claim 1 , wherein the sequence specific type I topoisomerase is a vaccinia topoisomerase.

3. The method of claim 1 , wherein the duplex DNA further comprises an affinity label at its 5′-terminus.

4. The method of claim 1 , wherein the duplex DNA is a plasmid.

5. The method of claim 4 , wherein the plasmid comprises a gene for ampicillin resistance.

6. The method of claim 1 , wherein the sequence specific type I topoisomerase is specific for a sequence selected from the group consisting of GCCCTTATTCCC (SEQ ID NO:1), TCGCCCTTATTC (SEQ ID NO:2), TGTCGCCCTTAT (SEQ ID NO:3), and GTGTCGCCCTTA (SEQ ID NO:4).

7. The method of claim 1 , wherein the donor duplex DNA further comprises a second topoisomerase cleavage site.

Assignments (1)
CONFIRMATORY LICENSE Recorded May 17, 2012
From: SLOAN-KETTERING INSTITUTE FOR CANCER RES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 028224/0126 →
Continuity (4)
Continuation 1036047800 · Feb 7, 2003
Continuation 0889851700 · Jul 22, 1997
Division 0835834400 · Dec 19, 1994
Related Publication 20060160072A1 · Jul 20, 2006